Accuray (ARAY) Projected to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY) is anticipated to post its Q1 2027 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.07) per share and revenue of $95.80 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last issued its earnings results on Wednesday, August 19th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $100.92 million for the quarter, compared to the consensus estimate of $105.30 million.

Accuray Price Performance

Accuray stock opened at $0.13 on Wednesday. Accuray has a one year low of $0.12 and a one year high of $1.58. The business has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.38. The firm has a market capitalization of $15.91 million, a P/E ratio of -0.33 and a beta of 1.42.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Weiss Ratings lowered Accuray from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 1st. BTIG Research restated a “neutral” rating on shares of Accuray in a research note on Wednesday, July 8th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Accuray currently has an average rating of “Reduce” and a consensus price target of $2.00.

About Accuray

Accuray Incorporated develops, manufactures and supports radiation oncology systems used to treat cancer. The company focuses on precision radiotherapy technologies designed to deliver targeted radiation while helping clinicians manage treatment complexity and limit exposure to surrounding healthy tissue.

Its principal product platforms include the CyberKnife System, a robotic, image-guided radiation therapy system used for radiosurgery and stereotactic body radiation therapy, and the Radixact System, an image-guided tomotherapy platform designed to deliver highly conformal radiation treatments.